Andain Inc. Announces Successful 510K Tests of Its Breakthrough Miniature Disposable Insulin Pump

BEVERLY HILLS, California, April 10, 2013 — /PRNewswire/ --

Andain Inc. (OTCQB: ANDN) ("Andain"), a company engaged in commercializing novel technologies in biotech, medical and life sciences fields through its accelerating incubator program, announces today of the successful 510K tests of its miniature disposable insulin pump.

Andain Inc. has successfully completed all of the required tests for the 510K regulation of its innovative miniature disposable insulin pump.

Andain's miniature disposable insulin pump is an ultra slim, small 'Band-Aid' patch size, fully disposable, water proof, fully programmable insulin pump designed to treat Type I and Type II diabetes for a one week period. The pump's dimensions are 49mm diameter by 7 mm thick 25 with 6CC insulin, making it very comfortable and almost unnoticeable to wear. Its ultra-low cost makes it an affordable yet clinically superior replacement for pen injector products. Smart on-line monitoring provides a real-time alert for occlusions and leakages.

The pump plug-in universal remote-control (PUR) unit provides the user, clinic, and doctor a dynamic control and on-going monitoring of the insulin treatment program.

"Our expert team meticulously monitored all tests process and results for the 510K regulation process, and providing full safety for our diabetics type II planed clinical trials." said Andain President and CEO Sam Elimelech.

Established in 2004 as a Nevada corporation with locations in Israel and the US, Andain Inc. (OTCBB: ANDN) commercializes novel technologies in the biotech & medical fields, specializing in identifying technical innovations and providing a unique incubator/accelerator development and industrial platform. The company also offers technical know-how and business strategy expertise to commercialize new technologies and deliver shareholder value

Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the company, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Technical complications that may arise could prevent the prompt implementation of any strategically significant plan(s) outlined above. The company cautions that these forward-looking statements are further qualified by other factors including, but not limited to, those set forth in the company's Form 10-K filing and other filings with the U S. Securities and Exchange Commission (available at http://www.sec.gov/). The company undertakes no obligation to publicly update or revise any statements in this release, whether as a result of new information, future events, or otherwise.

Contact:

Sam Elimelech CEO sam@andaininc.com +972-52-67-22212

SOURCE Andain Inc

Back to news